Indivior Pharmaceuticals, Inc. (INDV)
| Market Cap | 4.10B +30.7% |
| Revenue (ttm) | 1.33B +13.5% |
| Net Income | 356.00M +229.6% |
| EPS | 2.77 +227.7% |
| Shares Out | 118.01M |
| PE Ratio | 12.55 |
| Forward PE | 7.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,410,632 |
| Open | 34.68 |
| Previous Close | 34.56 |
| Day's Range | 33.93 - 34.82 |
| 52-Week Range | 24.28 - 42.81 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 49.00 (+41.13%) |
| Earnings Date | Oct 29, 2026 |
About INDV
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet... [Read more]
Financial Performance
In 2025, Indivior Pharmaceuticals's revenue was $1.24 billion, an increase of 4.29% compared to the previous year's $1.19 billion. Earnings were $210.00 million, an increase of 2900.00%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $49.0, which is an increase of 41.13% from the latest price.
News
Huron to replace Supernus in S&P 600 at open on November 2
Huron Consulting Group (HURN) will replace Supernus Pharmaceuticals (SUPN) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 2. Indivior Pharmaceuticals (INDV) is a...
Indivior to Report Third Quarter 2026 Financial Results
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 202...
Indivior Pharmaceuticals Transcript: EGM 2026
Stockholders approved the common-stock issuance connected to the merger. As a result, the proposed adjournment vote was not needed.
Indivior declares $8.13 per share special cash dividend
Indivior (INDV) announced that its board of directors declared a special cash dividend in the amount of $8.13 per share of Indivior common stock payable to holders of record of…
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special ...
Indivior price target lowered to $43 from $46 at Barclays
Barclays analyst Glen Santangelo lowered the firm’s price target on Indivior (INDV) to $43 from $46 and keeps an Overweight rating on the shares. The firm views the company’s merger…
Indivior price target raised to $53 from $50 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Indivior (INDV) to $53 from $50 and keeps a Buy rating on the shares following the company’s Q2 beat and…
Indivior Pharmaceuticals Slides: Corporate presentation
Indivior Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Indivior Pharmaceuticals Earnings Call Transcript: Q2 2026
A merger of equals will create a CNS biopharma leader with $2.2B pro forma revenue, $888M adjusted EBITDA, and five key growth products. The deal brings $125M in annual cost synergies, a strong balance sheet, and significant firepower for future business development.
Indivior Pharmaceuticals Earnings release: Q2 2026
Indivior Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Indivior Pharmaceuticals Slides: Q2 2026
Indivior Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Indivior Pharmaceuticals Quarterly report: Q2 2026
Indivior Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of m...
Indivior reports Q2 adjusted EPS $1.15, consensus 92c
Reports Q2 revenue $343M, consensus $307.55M. “Exceptional operational execution in Phase II – Accelerate – of the Indivior (INDV) Action Agenda fueled strong SUBLOCADE performance in the quarter and ...
Supernus and Indivior announce merger
Supernus Pharmaceuticals (SUPN) and Indivior (INDV) Pharmaceuticals (Nasdaq: INDV) entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leadi...
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
• Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million an...
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026,...
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
2024 results exceeded guidance, led by 20% Sublocade growth, but 2025 is forecast as a transition year with declining Suboxone Film revenue and flat Sublocade sales due to funding and competitive pressures. Cost reductions, litigation settlements, and focused R&D support long-term growth.
Indivior Pharmaceuticals Transcript: Transcript
Indivior Pharmaceuticals Transcript: Transcript
The session highlighted a strategic focus on SUBLOCADE growth, organizational simplification, and significant cost reductions, with a new operating model set for 2025-2026. Market share remains strong despite competition, and R&D is concentrated on two phase II assets, with further updates expected in early 2025.
Indivior Pharmaceuticals Transcript: Transcript
Indivior initiated with an Overweight at Barclays
Barclays initiated coverage of Indivior (INDV) with an Overweight rating and $46 price target The firm sees additional upside in the shares in fiscal 2026, driven by Indivior’s turnaround plan…
Indivior reports real-world data for Sublocade in opioid use disorder
Indivior (INDV) Pharmaceuticals announced results from two real-world evidence studies showing that adherence to extended-release buprenorphine, marketed as Sublocade, is associated with lower relapse...